(Q58097284)

1

Rosalyn J. Singleton

0 references

Jay C. Butler

2

Jay C. Butler

0 references

Lisa R. Bulkow

3

Lisa R. Bulkow

0 references

Alan J. Parkinson

7

Alan J. Parkinson

0 references

Debby A. Hurlburt

4

Debby Hurlburt

0 references

author name string

Katherine L. O’Brien

5

0 references

William Doan

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

6

0 references

language of work or name

English

0 references

publication date

March 2007

0 references

published in

Vaccine

0 references

volume

25

0 references

issue

12

0 references

page(s)

2288-2295

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

High incidence rates of invasive pneumococcal disease in the White Mountain Apache population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Epidemiology of Invasive Streptococcus pneumoniae among Navajo Children in the Era before Use of Conjugate Pneumococcal Vaccines, 1989-1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Invasive pneumococcal disease among Navajo adults, 1989-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Persistence of Pneumococcal antibodies in human subjects following vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Reactivity and antibody responses of volunteers given two or three doses of pneumococcal vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Risk factors for acquiring pneumococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Alcohol abuse among Native Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

A systematic approach for increasing pneumococcal vaccination rates at an inner-city public hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Pneumococcal vaccination in the emergency department: an assessment of need

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065

inferred from DOI database lookup

7 January 2021

based on heuristic

Pneumococcal Vaccine: Dose, Revaccination, and Coadministration with Influenza Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.065